About Bioaffinity technologies
Bioaffinity technologies is a company based in San Antonio (United States) founded in 2014. Bioaffinity technologies has raised $9.05 million across 6 funding rounds from investors including sanantonioedf. The company has 57 employees as of December 31, 2024. Bioaffinity technologies offers products and services including CyPath Lung and OncoSelect Therapeutics. Bioaffinity technologies operates in a competitive market with competitors including Cytek Biosciences, ACEA Biosciences, Accuri Cytometers, IntelliCyt and Orflo, among others.
- Headquarter San Antonio, United States
- Employees 57 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bioaffinity Technologies, Inc.
-
Annual Revenue
$9.36 M (USD)269.68as on Dec 31, 2024
-
Net Profit
-$9.04 M (USD)-13.89as on Dec 31, 2024
-
EBITDA
-$8.35 M (USD)-8.08as on Dec 31, 2024
-
Total Equity Funding
$9.05 M (USD)
in 6 rounds
-
Latest Funding Round
$1.2 M (USD), Post-IPO
Aug 14, 2025
- Investors
-
Employee Count
57
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bioaffinity technologies
Bioaffinity technologies is a publicly listed company on the NASDAQ with ticker symbol BIAF in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Bioaffinity technologies
Bioaffinity technologies offers a comprehensive portfolio of products and services, including CyPath Lung and OncoSelect Therapeutics.
Non-invasive test using flow cytometry for early lung cancer detection.
Research on cancer-selective therapies targeting tumor cells.
People of Bioaffinity technologies
Unlock access to complete
Unlock access to complete
Funding Insights of Bioaffinity technologies
Bioaffinity technologies has successfully raised a total of $9.05M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.2 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bioaffinity technologies
Bioaffinity technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include sanantonioedf.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides recruitment services to connect organizations with qualified candidates.
|
Locked | Locked | Locked |
Investor details for Bioaffinity technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bioaffinity technologies
Investment portfolio details for Bioaffinity technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bioaffinity technologies
Detailed financials for Bioaffinity technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioaffinity Technologies Comparisons
Peer comparison for Bioaffinity technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bioaffinity technologies
Bioaffinity technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cytek Biosciences, ACEA Biosciences, Accuri Cytometers, IntelliCyt and Orflo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Advanced flow cytometry systems are manufactured for research applications.
|
|
| Locked | Locked | Locked |
Instruments for life science research are developed and marketed.
|
|
| Locked | Locked | Locked |
Compact flow cytometers for cell analysis are developed and provided.
|
|
| Locked | Locked | Locked |
Screening solutions are provided using bead-based and cell-based assays.
|
|
| Locked | Locked | Locked |
Instrumentation for cell and protein analysis is developed and marketed.
|
|
| Locked | Locked | Locked |
Offers technology for cell analysis, purification, and processing.
|
Detailed competitors of Bioaffinity technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioaffinity Technologies
Complete news archive for Bioaffinity technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioaffinity technologies
Bioaffinity technologies was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Bioaffinity technologies is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Bioaffinity technologies is a funded company, having raised a total of $9.05M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Bioaffinity technologies is 57.
Annual revenue of Bioaffinity technologies is $9.36M as on Dec 31, 2024.
Bioaffinity Technologies was founded in 2014 in San Antonio, United States, within the biotechnology sector. Operations focus on designing diagnostic and therapeutic platforms for various cancers. In vitro diagnostics (IVD) are developed alongside targeting methods for cancer cells. The initial product, CyPath, utilizes a biolabel that induces fluorescence in cancer cells to enable detection. Activities emphasize early identification and treatment options in oncology.
Bioaffinity technologies's top competitors include Cytek Biosciences, Accuri Cytometers and ACEA Biosciences.
Bioaffinity technologies offers CyPath Lung and OncoSelect Therapeutics.
Yes, Bioaffinity technologies is publicly traded on NASDAQ under the ticker symbol BIAF.
Bioaffinity technologies has 1 investor. Key investors include sanantonioedf.
The ticker symbol of Bioaffinity technologies is BIAF on NASDAQ.